413 Improvement in itch, symptoms and quality of life with upadacitinib through week 16 in adults and adolescents with atopic dermatitis: results from phase 3 studies (Measure Up 1, Measure Up 2 and AD Up)

被引：1
作者：
Lio, Peter [1 ]
Eichenfield, Lawrence F. [2 ,3 ,4 ]
Marcoux, Danielle [5 ]
Lee, Wan-Ju [6 ]
Teixeira, Henrique D. [6 ]
Raymundo, Eliza M. [6 ]
Gamelli, Amy E. [6 ]
Grada, Ayman [6 ]
Hu, Xiaofei [6 ]
Irvine, Alan D. [7 ,8 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL USA
[2] Univ Calif San Diego, Dept Dermatol, San Diego, CA USA
[3] Univ Calif San Diego, Dept Pediat, San Diego, CA USA
[4] Rady Childrens Hosp San Diego, San Diego, CA USA
[5] Univ Montreal, St Justine Univ Hosp Ctr, Dept Pediat, Div Dermatol, Montreal, PQ, Canada
[6] AbbVie Inc, N Chicago, IL USA
[7] Trinity Coll Dublin, Dept Clin Med, Dublin, Ireland
[8] Childrens Hlth Ireland, Dermatol, Crumlin, Ireland
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2023年 / 188卷
关键词：
D O I：
10.1093/bjd/ljad162.033
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
413
引用
收藏
页数：2
相关论文
共 50 条
[21]   Upadacitinib with or without topical corticosteroids improves health-related quality of life in adolescent and adult patients with moderate-to-severe atopic dermatitis: results from three phase III studies (Measure Up 1, Measure Up 2 and AD Up) [J].
Prajapati, Vimal H. ;
Rosmarin, David ;
Shumack, Stephen ;
Calimlim, Brian M. ;
Takemoto, Shunya ;
Hu, Xiaofei ;
Ladizinski, Barry ;
Warren, Richard B. .
BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) :E81-E81
[22]   Rapid and sustained improvements in itch and quality of life with upadacitinib plus topical corticosteroids in adults and adolescents with atopic dermatitis: 52-week outcomes from the phase 3 AD Up study [J].
Magnolo, Nina ;
Cameron, Michael C. ;
Shahriari, Mona ;
Geng, Bob ;
Calimlim, Brian M. ;
Teixeira, Henrique ;
Hu, Xiaofei ;
Yang, Yang ;
Liu, Yingyi ;
Zhang, Shiyu ;
Sanchez, Cristina Sancho ;
Altman, Katherine ;
Langley, Richard G. .
JOURNAL OF DERMATOLOGICAL TREATMENT, 2024, 35 (01)
[23]   The effect of upadacitinib on the genital region in moderate-to-severe atopic dermatitis: an analysis from the Measure Up 1 and Measure Up 2 studies [J].
Cather, Jennifer ;
Magnolo, Nina ;
Cameron, Michael ;
Calimlim, Brian ;
Lane, Michael ;
Hays, Stephanie ;
Gamelli, Amy ;
Woo, Yu Ri .
BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
[24]   Effects of upadacitinib on the patient-reported impact of atopic dermatitis: Atopic Dermatitis Impact Scale (ADerm-IS) - results from two pivotal phase III studies (MEASURE UP 1 and MEASURE UP 2) [J].
Simpson, E. L. ;
De Bruin-Weller, M. S. ;
Prajapati, V. H. ;
Calimlim, B. M. ;
Teixeira, H. D. ;
Zeng, J. ;
Liu, M. ;
Silverberg, J. I. .
BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) :E124-E124
[25]   Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2) [J].
Simpson, Eric L. ;
Prajapati, Vimal H. ;
Leshem, Yael A. ;
Chovatiya, Raj ;
de Bruin-Weller, Marjolein S. ;
Staender, Sonja ;
Pink, Andrew E. ;
Calimlim, Brian M. ;
Lee, Wan-Ju ;
Teixeira, Henrique ;
Ladizinski, Barry ;
Hu, Xiaofei ;
Yang, Yang ;
Liu, Yingyi ;
Liu, Meng ;
Grada, Ayman ;
Platt, Andrew M. ;
Silverberg, Jonathan I. .
DERMATOLOGY AND THERAPY, 2024, 14 (05) :1127-1144
[26]   EFFECT OF UPADACITINIB ON INTENSITY OF SCORAD ITEMS AND IMPACTS TO ITCH AND SLEEP: ANALYSIS FROM THE MEASURE UP 1 AND MEASURE UP 2 STUDIES [J].
Cameron, Michael ;
Magnolo, Nina ;
Prajapati, Vimal H. ;
Haque, Adel ;
Lee, Wan-Ju ;
Altman, Katherine ;
Platt, Andrew M. ;
Lane, Michael C. ;
Calimlim, Brian M. ;
Taieb, Alain .
ACTA DERMATO-VENEREOLOGICA, 2023, 103 :56-57
[27]   Achieving incrementally greater skin improvement thresholds with upadacitinib in moderate-to-severe atopic dermatitis: a pooled analysis of two phase III studies (Measure Up 1 and Measure Up 2) [J].
Reich, K. ;
Langley, R. G. ;
Calimlim, B. M. ;
Teixeira, H. D. ;
Zeng, J. ;
Silverberg, J. I. .
BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) :E131-E132
[28]   Ef-ficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD UpRandomized Clinical Trials [J].
Paller, Amy. S. .
JAMA DERMATOLOGY, 2024, 160 (05) :582-582
[29]   The multidimensional burden of moderate-to-severe atopic dermatitis: a pooled analysis of baseline data from three phase III studies (Measure Up 1, Measure Up 2 and AD Up) [J].
Silverberg, J. I. ;
Thyssen, J. P. ;
Costanzo, A. ;
Calimlim, B. M. ;
Tenorio, A. R. ;
Chen, N. ;
Gooderham, M. J. .
BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) :E126-E127
[30]   Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double- blind, randomised controlled phase 3 trials [J].
Guttman-Yassky, Emma ;
Teixeira, Henrique D. ;
Simpson, Eric L. ;
Papp, Kim A. ;
Pangan, Aileen L. ;
Blauvelt, Andrew ;
Thaci, Diamant ;
Chu, Chia-Yu ;
Hong, H. Chih-Ho ;
Katoh, Norito ;
Paller, Amy S. ;
Calimlim, Brian ;
Gu, Yihua ;
Hu, Xiaofei ;
Liu, Meng ;
Yang, Yang ;
Liu, John ;
Tenorio, Allan R. ;
Chu, Alvina D. ;
Irvine, Alan D. .
LANCET, 2021, 397 (10290) :2151-2168
12345